These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23082249)

  • 1. The Global Economic Cost of Osteoarthritis: How the UK Compares.
    Chen A; Gupte C; Akhtar K; Smith P; Cobb J
    Arthritis; 2012; 2012():698709. PubMed ID: 23082249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(10):1-66. PubMed ID: 23074461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic impact of sight loss and blindness in the UK adult population.
    Pezzullo L; Streatfeild J; Simkiss P; Shickle D
    BMC Health Serv Res; 2018 Jan; 18(1):63. PubMed ID: 29382329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare and wider societal implications of stillbirth: a population-based cost-of-illness study.
    Campbell HE; Kurinczuk JJ; Heazell A; Leal J; Rivero-Arias O
    BJOG; 2018 Jan; 125(2):108-117. PubMed ID: 29034559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies.
    Salmon JH; Rat AC; Sellam J; Michel M; Eschard JP; Guillemin F; Jolly D; Fautrel B
    Osteoarthritis Cartilage; 2016 Sep; 24(9):1500-8. PubMed ID: 27034093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee.
    Watson M; Brookes ST; Faulkner A; Kirwan J
    Cochrane Database Syst Rev; 2007 Jul; 2006(1):CD000142. PubMed ID: 17636601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The projected burden of primary total knee and hip replacement for osteoarthritis in Australia to the year 2030.
    Ackerman IN; Bohensky MA; Zomer E; Tacey M; Gorelik A; Brand CA; de Steiger R
    BMC Musculoskelet Disord; 2019 Feb; 20(1):90. PubMed ID: 30797228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
    Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
    Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression: cost-of-illness studies in the international literature, a review.
    Berto P; D'Ilario D; Ruffo P; Di Virgilio R; Rizzo F
    J Ment Health Policy Econ; 2000 Mar; 3(1):3-10. PubMed ID: 11967432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Societal costs of chemotherapy in the UK: an incidence-based cost-of-illness model for early breast cancer.
    Parsekar K; Howard Wilsher S; Sweeting A; Patel A; Fordham R; ; ; ; ;
    BMJ Open; 2021 Jan; 11(1):e039412. PubMed ID: 33431487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct economic burden of mental health disorders associated with polycystic ovary syndrome: Systematic review and meta-analysis.
    Yadav S; Delau O; Bonner AJ; Markovic D; Patterson W; Ottey S; Buyalos RP; Azziz R
    Elife; 2023 Aug; 12():. PubMed ID: 37534878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying the mental health and economic impacts of prospective Universal Basic Income schemes among young people in the UK: a microsimulation modelling study.
    Chen T; Reed H; Parra-Mujica F; Johnson EA; Johnson M; O'Flaherty M; Collins B; Kypridemos C
    BMJ Open; 2023 Oct; 13(10):e075831. PubMed ID: 37793925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of schizophrenia in England.
    Mangalore R; Knapp M
    J Ment Health Policy Econ; 2007 Mar; 10(1):23-41. PubMed ID: 17417045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A harm reduction model to assess the impact of new treatments for pain over standard of care among patients with osteoarthritis.
    Silverman S; Schepman P; Rice JB; Robinson RL; White AG; Fernan C; Beck CG
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1652-1660. PubMed ID: 34818088
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.
    Lafuma A; Brézin A; Lopatriello S; Hieke K; Hutchinson J; Mimaud V; Berdeaux G
    Pharmacoeconomics; 2006; 24(2):193-205. PubMed ID: 16460138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structured Education and Neuromuscular Exercise Program for Hip and/or Knee Osteoarthritis: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2018; 18(8):1-110. PubMed ID: 30443280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of disorders of the brain in Europe 2010.
    Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jönsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen HC; Stovner LJ; Vallat JM; Van den Bergh P; van Os J; Vos P; Xu W; Wittchen HU; Jönsson B; Olesen J;
    Eur Neuropsychopharmacol; 2011 Oct; 21(10):718-79. PubMed ID: 21924589
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.